ETF profile for iShares Genomics Immunology And Healthcare ETF (IDNA) from the issuer: top holdings, net assets, expense ratio and shares outstanding.
IDNA ETF Profile
| Family: |
Blackrock (iShares) |
| Name: |
iShares Genomics Immunology and Healthcare ETF |
|
|
| Inception Date: |
11-Jun-2019 |
| Termination Date: |
|
| Investment Objective: |
The iShares Genomics Immunology and Healthcare ETF seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering. |
|
|
| Prospectus |
|
|
|
| Top 10 Holdings |
|
|
| MODERNA |
MRNA |
14.6216% |
| GENMAB |
GMAB |
5.9833% |
| TWIST BIOSCIENCE |
TWST |
4.9397% |
| REGENERON PHARMACEUTICALS |
REGN |
4.2107% |
| BAYER AG |
BAYN |
4.2057% |
| TAKEDA PHARMACEUTICAL |
4502 |
3.7828% |
| EXELIXIS INC |
EXEL |
3.7399% |
| VERTEX PHARMACEUTICALS |
VRTX |
3.4154% |
| MERCK & CO INC |
MRK |
3.3999% |
| REVOLUTION MEDICINES |
RVMD |
3.3776% |
|
Top 10 Holdings Weight: |
51.7% |
| Number of Holdings: |
63 |
| Shares Outstanding: |
8,350,000 |
| Total Net Assets: |
352,536,992 |
| NAV: |
42.17 |
| Net Expense Ratio: |
0.47% |
|
|
| Asset Class: |
Equities (Stocks) |
| Developed or Emerging: |
Developed Market Funds |
| Country: |
|
| Region: |
|
| Strategy: |
|
| Currency: |
|
| Commodity: |
|
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Dividend Type: |
|
| Tax Exempt State: |
|
| Maturity Duration: |
|
| Market Cap: |
Broad Market / Multi-Cap |
| Credit Quality: |
|
| Mortgage Bond Types: |
|
| Bond Type: |
|
| Gov't Bond Types: |
|
| Reit Type: |
|
| Leverage Direction/Factor: |
|
| Is Currency Hedged: |
No |
| US or Ex-US: |
Global |
